Company Restates Financials and Uses Nasdaq for Stock Sales
What happened
A company restated its condensed consolidated interim financial statements for June 30, 2026, and December 31, 2025. The restatement was initiated after the audit committee found valuation errors in stock options and certain warrant derivative liabilities, errors that spanned from fiscal year 2020 through June 30, 2026. The company sold 949,700 common shares under its at-the-market program, generating gross proceeds of C$2.77 million.
From tickerreport.com
Why it matters
The restatement affected liabilities, common shares, reserves, deficit, and reported earnings. Despite the changes, the company stated that the errors did not impact cash flows or cash runway. At June 30, 2026, the company reported cash and cash equivalents of C$86.79 million.
From tickerreport.com
Who's involved
- NasdaqAmerican fully electronic stock exchange where the company utilized its at-the-market program
Keep exploring
The entities involved
-
Nasdaq
American fully electronic stock exchange
Related events
- Amgen Inc. trades on the NASDAQ stock exchange.
- Janux Therapeutics, Inc. was listed on the Nasdaq stock exchange on July 28, 2026.
- Nasdaq, Inc. is identified as a multinational financial technology services corporation.
- Praxis Precision Medicines listed its shares on the Nasdaq stock exchange on July 17, 2026.
- Regeneron Pharmaceuticals stock is traded on the Nasdaq exchange.